By Bruce Buckley
The pipeline for cell and gene therapies is exploding, with nearly 400 products in development and more than 100 mostly rare diseases and conditions under study for potential treatment, Brian Corvino, MBA, a managing director at Deloitte Consulting, said at the AMCP Nexus 2020 virtual meeting.
“We have the prospect of therapies that are truly curative in nature,” Corvino noted. “They’ve shown both high efficacy and the potential to disrupt existing therapy